Wednesday, October 26, 2016

The Changing HCV Landscape: Update on Treatment

Gastroenterology & Endoscopy News

The Changing HCV Landscape: Update on Treatment
Review Article
OCTOBER 26, 2016
DAAs for HCV infection have all but replaced IFN as the foundation of treatment for HCV across all genotypes. Among the major advantages of these oral regimens, beyond their remarkable efficacy, has been their relatively clean safety profile. Adverse effects are common but generally mild, including headache, fatigue, and insomnia—and are trivial relative to the effects of earlier regimens, reflected by a low rate of discontinuation for adverse events. Clinicians must be aware of potential drug–drug interactions, and should prescribe these medications with a commitment toward mastering these and/or consulting the numerous published and online references, including package inserts, containing this information...

Continue to article....

No comments:

Post a Comment